Terns Pharmaceuticals
TERN
TERN was delisted on the 4th of May, 2026.
42 hedge funds and large institutions have $26.4M invested in Terns Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 13 closing their positions.
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
5% less funds holding
Funds holding: 44 → 42 (-2)
8.39% less ownership
Funds ownership: 66.63% → 58.24% (-8.4%)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
47% less capital invested
Capital invested by funds: $50M → $26.4M (-$23.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.52M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.4M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$801K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$754K |
| 5 |
AC
Armistice Capital
New York
|
+$645K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.97M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.43M |
| 3 |
BlackRock
New York
|
-$1.17M |
| 4 |
AC
Antara Capital
New York
|
-$400K |
| 5 |
State Street
Boston,
Massachusetts
|
-$286K |
TERN Hedge Fund Activity: Q2 2022 in Review
42 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q2 2022, worth a combined $26.4M — down 47% from $50M a quarter earlier.
Fund positioning in TERN was balanced in Q2 2022: 13 funds opened new positions, 13 closed out, 11 added to existing stakes and 13 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $2.52M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.97M sold.
- 42 institutional investors held Terns Pharmaceuticals (TERN) as of Q2 2022, down from 44 in Q1 2022.
- Funds reported $26.4M of Terns Pharmaceuticals stock for Q2 2022, down 47% quarter-over-quarter.
- 13 funds opened new Terns Pharmaceuticals positions in Q2 2022 and 13 closed out, a net change of 0 holders.
- The largest Terns Pharmaceuticals buyer in Q2 2022 was RA Capital Management, an estimated $2.52M added.
- The largest Terns Pharmaceuticals seller in Q2 2022 was Deerfield Management, an estimated $6.97M sold.
Based on aggregated 13F filings for Q2 2022.